Gufic Biosciences has entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.
Under this initiative, Gufic will undertake mutually agreed development activities in return for the exclusive commercial rights for Selvax immunotherapy in India along with an equal share of future revenues that might be derived from sales of the product in Europe, subject to the approvals received from the regulatory authorities in India and Europe, respectively.

Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours. It was formed following a breakthrough in cancer research where researchers at Curtin University West Australia, came to understand the sophisticated methods used by tumours to evade the body's immune system. This has allowed the research team of Selvax to develop a selfvaccine approach where the body's immune system is harnessed rather than hindered in treating cancer.

A major advantage of the Selvax technology is that it targets the tumour microenvironment in cancer cells and stimulates an immune response. This allows the technology to overcome major challenges previously faced with other cancer immunotherapies including poor response rates and potentially serious toxicity. It is envisaged that the successful development of the technology will provide novel cancer treatments for animals and humans.

Gufic continues its efforts to bring innovation in the medical field by expanding its portfolio in cancer immunotherapy, which is one of the most rapidly growing segments of the global pharmaceutical market.